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INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are rela-
tively rare and represent3% of all gastrointestinal
neoplasms, however, they are the most common
mesenchymal tumor of the gastrointestinal tract (1).
Approximately 70% of all GISTs are found in the
stomach, 20% originate from the small intestine, and
10% are found elsewhere (2).
We retrospectively evaluated 18F-fluorodeoxyglu-
cose (FDG) uptake and pathological risk category.
We also evaluated response to therapy with imatinib
mesylate. We investigated the possibility of deter-
mining the pathological risk category by 18F-FDG
positron emission tomography/computed tomogra-
phy (18F-FDG PET/CT).
PATIENTS AND METHODS
This retrospective study was approved by the
Ethics Committee of the Tokushima University
Hospital. We retrospectively reviewed the results
of 29 consecutive 18F-FDG PET/CT studies in 20
patients (14 male, 6 female, 44-85 years old) with
GISTs between October 2005 and December 2009.
18F-FDG was synthesized by the nucleophilic sub-
stitution method using an 18F -FDG-synthesizing
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instrument F100 (Sumitomo Heavy Industries, Ltd.,
Tokyo, Japan) and a cyclotron CYPRIS (Sumitomo
Heavy Industries, Ltd.) in our institution. All patients
were examined with PET/CT scanner (Aquiduo,
Toshiba Medical Systems Corporation, Tochigi,
Japan) 1 hour after FDG injection (3.7 MBq/kg).
They were imaged from the top of the head to the
middle of thigh. The attenuation - corrected PET
image, non-attenuation-corrected PET image and
CT image were reviewed, and the attenuation-cor-
rected PET and CT image were co-registered us-
ing AquariusNET viewer (TeraRecon, Inc.). Eleven
of the 20 patients underwent PET/CT prior to ther-
apy. Three of these eleven patients also underwent
follow-up PET/CT after operation or imatinib ther-
apy. Nine of the 20 patients underwent PET/CT
only after operation. Three of these nine patients
had recurrent GIST. Of the eleven patients who
underwent PET/CT prior to therapy, the primary
tumor was located in the stomach in six patients,
in the duodenum in two, and the small intestine in
three.
The risk category was determined pathologi-
cally by tumor size and the number of mitotic cells
(Table 1) (3).
RESULTS
Tumor size, primary site, maximum standard-
ized uptake value (SUVmax), and risk category of
20 patients who underwent PET/CT are presented
in Table 2. All eleven lesions were FDG-positive
upon pre-treatment PET/CT (SUVmax 2.2-15.7,
Table 2. Primary site, tumor size, SUVmax, risk category and treatment outcome of 20 GIST patients
Pt.
no.
Age (y)/
gender Primary site
Size
(cm)
SUVmax
Risk category Treatment Follow-upperiod (mo) Outcome
PET/CT
Prior to
therapy
Follow-up PET/CT
after operation
or chemotherapy
1 62/M stomach 3.5x3 3.0 - low op 1 rec (-)
2 72/F stomach 5x3.5 3.0 abnormal uptake (-) low op 23 rec (-)
3 72/M small intestine 5x4 2.2 - low op 24 rec (-)
4 62/F stomach 5.4x5.2 3.3 abnormal uptake (-) intermediate op 38 rec (-)
5 54/M stomach 21x5.5 10.0 - high neoadjuvant+op+adjuvant 27 rec (-)
6 65/M stomach 7x4 14.3 - high op+adjuvant chemo 12 rec (-)
7 49/M stomach 11x7.4 15.7 - high chemo 3 PR
8 50/M duodenum 11x10 8.0 5.010.0 high chemo 32* PRPD
9 66/M duodenum 14x7.5 10.7 - high op 1 rec (-)
10 57/M small intestine 12x6.5 8.8 - high op 29 rec (-)
11 71/M small intestine 7x4.5 15.0 - high op+adjuvant chemo 25* rec (+)
12 61/M stomach - - 8.7 (liver meta.) unknown op+adjuvant chemo 40 rec (+)
13 85/M duodenum - - 5.5 (abdominal mass) unknown op+adjuvant chemo 28 rec (+)
14 73/M rectum - - 2.5 (pelvic mass) high neoadjuvant+op+adjuvant 66 rec (+)
15 59/M stomach - - abnormal uptake (-) unknown op+adjuvant chemo 67 rec (+)CR
16 62/F stomach - - abnormal uptake (-) unknown op+adjuvant chemo 85 rec (+)CR
17 79/F stomach - - abnormal uptake (-) high op+adjuvant chemo 68 rec (-)
18 58/M stomach - - abnormal uptake (-) unknown op+adjuvant chemo 175 CRrec (+)
19 44/F sigmoid colon - - abnormal uptake (-) high op 50 rec (-)
20 52/F unknown - - abnormal uptake (-) unknown op+adjuvant chemo 84 rec (+)CR
*Patient died.
Pt. no. 10 underwent PET/CT once after therapy. Pt. nos. 8, 17 underwent PET/CT twice after therapy. Pt. nos. 4, 19 underwent PET/CT three
times after therapy.
SUVmax : maximum standardized uptake value
GIST : gastrointestinal stromal tumor
PET/CT : positron emission tomography/computed tomography
Table 1. Risk category
Tumor size
(cm)
Number of mitotic cells
per 50 high-power fields
Very low 2 5
Low 2-5 5
Intermediate
5
5-10
6-10
5
High
5
10
Any size
5
Any mitotic rate
10
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average 8.5). Seven of eleven primary lesions were
categorized as high risk, and showed intense FDG
uptake with SUVmax of 8.0, 8.8, 10.0, 10.7, 14.3,
15.0 and 15.7. Four of eleven primary lesions were
categorized as low and intermediate risk and showed
much lower FDG uptake (low risk : SUVmax 2.2,
3.0 and 3.0 ; intermediate risk : SUVmax 3.3). There
was a significant difference between the SUVmax of
the primary lesions categorized as high risk (11.8
3.15) and that of the primary lesions categorized
as low and intermediate risk (2.880.47) (p0.001)
(Fig. 1). All recurrent tumors showed high FDG
uptake except for one case. The recurrent tumor of
this case, confirmed high-risk at initial diagnosis,
showed relatively low uptake (SUVmax 2.5). Six of
the nine patients who underwent PET/CT only af-
ter operation had no abnormal FDG uptake on
PET/CT.
CASE 1
A 72 -year - old woman had a mass behind the
stomach, which measured 5.03.5 cm, and showed
mild FDG uptake with an SUVmax of 3.0 on PET/
CT (Fig. 2). The abdominal mass was resected and
Fig. 1. Comparison of SUVmax (meanSD) of the primary lesions categorized as high risk and that of the primary lesions cate-
gorized as low and intermediate risk. The SUVmax of the primary lesions categorized as high risk was significantly higher than that
of the primary lesions categorized as low and intermediate risk (11.83.15 vs 2.880.47 ; p0.01).
Fig. 2. Transaxial CT (left), FDG-PET (middle), and fusion (right) images of the abdomen in a 72-year-old woman with GIST cate-
gorized as low risk. The tumor was behind the stomach, measured 5.03.5 cm, and showed mild FDG uptake with an SUVmax of
3.0 (arrow).
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confirmed pathologically as GIST of the stomach,
and categorized as low risk. No recurrence and me-
tastasis were detected on follow-up PET/CT per-
formed 3.5 months after the operation.
CASE 2
A 50-year-old man had an abdominal mass near
the pancreatic body, which showed intense FDG
uptake (SUVmax 8.0) (Fig. 3a). Tumor with ulcer
formation was detected in the horizontal part of the
duodenum at endoscopy. For biopsy, the mass was
confirmed pathologically as GIST of the duodenum
and categorized as high risk. Systemic chemother-
apy with imatinib mesylate was started as neoadju-
vant therapy. Follow-up PET/CT was performed 4
months after chemotherapy showed a reduction in
tumor size and decreased FDG uptake (SUVmax
5.0) (Fig. 3b). However, follow-up PET/CT at 10
months after chemotherapy showed tumor enlarge-
ment and increased FDG uptake (SUVmax 10.0)
(Fig. 3c).
DISCUSSION
All primary GISTs and recurrent tumors can be
detected by 18F-FDG PET/CT. GIST can be shown
to be FDG-positive, with a varying degree of uptake.
Isis G et al. reported the sensitivity of GISTs includ-
ing metastatic lesions by FDG-PET was 86% (1).
Kamiyama et al. reported that the sensitivity of
GISTs by FDG-PET was 100% (4). FDG uptake and
pathological risk category may have some relation-
ship. It has been reported that a high rate of FDG
uptake in GIST indicates high metabolism and ma-
lignant potential (4). There have been many reports
that FDG accumulation and grade of malignancy are
correlated with each other (4, 5). Kamiyama et al.
reported that there was a significant difference be-
tween the SUV of the primary lesions categorized as
high and intermediate risk (6.521.15) and that of
the primary lesions categorized as low risk (2.18
0.06) (p0.01) (4, 5). In our study, all the primary
high - risk GISTs showed intense FDG uptake
(SUVmax 11.83.15). The low- and intermediate-
risk GISTs also showed FDG uptake (SUVmax
a
b
c
Fig. 3. Transaxial CT (left), FDG-PET (middle), and fusion (right) images of the abdomen in a 50-year-old man with GIST cate-
gorized as high risk. The abdominal tumor showed intense FDG uptake (SUVmax 8.0) (a, arrow). Reduction in tumor size and lower
FDG uptake (SUVmax 5.0) were observed on a PET/CT image (b, arrow) performed 4 months after chemotherapy with imatinib
mesylate, but tumor enlargement and increased FDG uptake (SUVmax 10.0) were observed on a PET/CT image (c, arrow) performed
10 months after chemotherapy.
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2.880.47). The SUVmax of the primary lesions
categorized as high risk was significantly higher
than that of the primary lesions categorized as low
and intermediate risk. This observation suggested
that the degree of FDG uptake may be a useful in-
dicator of risk category. The size of the recurrent
tumor in patient No.14 was small (about 1 cm).
FDG uptake depends on spatial resolution of the
PET/CT system and a partial volume effect may
decrease FDG uptake, which leads to low SUV in a
small tumor (6). Therefore, this recurrent tumor
showed relatively low uptake (SUVmax 2.5) in spite
of being high-risk.
The patients of GIST post operation showing no
abnormal FDG uptake on PET/CT are clinically
considered as no recurrence and no metastasis.
PET/CT is useful for follow-up examinations of
GIST post operation.
In case 2, follow-up PET/CT performed 4 months
after chemotherapy showed a reduction in tumor
size and lower FDG uptake. Imatinib mesylate was
considered to be effective, but follow-up PET/CT
performed 10 months after chemotherapy showed
tumor enlargement and increased FDG uptake. This
was considered to be indicative of resistance to
imatinib mesylate (7). It has been reported that
many GISTs may not change significantly in size
during early response to imatinib mesylate admini-
stration (8). PET has been shown to be highly sen-
sitive in detecting early response to imatinib me-
sylate therapy (8, 9). It has been reported that den-
sity reduction on CT reflects necrotic changes in
the tumor and is a predictor of early response to
imatinib mesylate therapy. However, it is relatively
difficult to evaluate early response to imatinib me-
sylate therapy by CT alone (8, 10). If a tumor tem-
porarily grew larger as an early response to imatinib
mesylate therapy, it might be evaluated as show-
ing a lack of response to imatinib mesylate therapy
(10). By means of PET/CT, we can evaluate re-
sponse to imatinib mesylate therapy before tumor
shrinkage.
It may be that GISTs in pathologically high-risk
patients have high glucose metabolism (4). Since
18F-FDG PET/CT can evaluate glucose metabolism,
it may be a useful tool for determining GIST risk
category.
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